Lantheus Holdings, the parent company of Lantheus Medical Imaging, has entered into a strategic collaboration and license agreement with biopharmaceutical firm NanoMab Technology to develop next-generation radiopharmaceuticals for immuno-oncology therapies.
This partnership is designed to provide imaging biomarker research tools to pharmaceutical companies and academic centers conducting research and development on immuno-oncology treatments, including combination therapies.
Lantheus will license NanoMab's NM-01 proprietary radiopharmaceutical biomarker camelid single-domain antibody that has demonstrated a high affinity for PD-L1 protein. If validated, NM-01 may provide a specific, noninvasive approach to diagnosis.
NM-01 currently is in phase 1 clinical development. The agent has a short half-life and is designed to offer diagnostically significant results in approximately two hours. NanoMab plans to file an investigational medicinal product dossier (IMPD) in the U.K. in the second half of this year.
